Varicella-zoster virus vasculopathy in a patient with multiple sclerosis receiving natalizumab Authors: Anna Elmståhl, Fredrik Buchwald, Andreea Ilinca Published: 2023 ABSTRACT We present a case of a woman in her 30s with relapsing-remitting multiple sclerosis, treated with natalizumab, who developed ophthalmic varicella zoster virus (VZV) infection, with subsequent vasculopathy causing cerebral ischaemic lesions. She was treated with acyclovir, prednisolone and acetylsalicylic acid and fully recovered. VZV vasculopathy is associated with stroke and immunomodulating treatments may increase the risks of these adverse events. To date, nine VZV-related vasculopathy cases in patients treated with natalizumab have been reported in English literature and are summarised in this paper. Although rare, VZV intracerebral vasculopathy is an important differential diagnosis in patients with unexplained new-onset neurological symptoms after a herpes zoster infection. Treatment guidelines for VZV vasculopathy and for continuing treatment of multiple sclerosis after such an event are currently not established. Background Cerebral vasculopathy caused by varicella zoster virus (VZV) has been associated with stroke in both adults and children. The risk of stroke appears to be greatest within the first months after herpes zoster but might persist up to 1 year. The correlation between age and ophthalmic/cerebral zoster episode and stroke remains unclear; some authors suggest a higher risk of stroke at younger ages, under 40 and 60 years of age, respectively, while other publications indicate an increased risk of stroke at the age over 45 years. Immunocompromised individuals, due to drugs or disease, are more susceptible to central nervous system-associated vasculopathy.1–5 Patients with the chronic autoimmune disease multiple sclerosis (MS) have been treated with immunomodulating drugs since the 1990s and natalizumab was introduced 2006.6 Natalizumab is a humanised monoclonal IgG4 antibody which decreases the CD4+/CD8+ ratio in the cerebrospinal fluid (CSF) compared with the peripheral blood. By blocking the α4-subunit of α4β1-integrin (very late antigen-4, VLA-4) on activated immune cells, VLA-4 mediated transmigration of the activated immune cells is hindered, resulting in impaired immune surveillance.7 8 Patients treated with natalizumab appear to have an increased risk for herpes infections and JC-virus associated progressive multifocal leukoencephalopathy.7 9 10 We present the case of a woman in her 30s with relapsing-remitting MS with natalizumab treatment, who experienced ischaemic stroke after an ophthalmic zoster infection. Case presentation A woman in her 30s with natalizumab-treated MS contacted our neurological outpatient clinic due to a new onset headache that started 2 months after a right-sided ophthalmic zoster infection. She had no vascular risk factors, migraine or any other neurological or inflammatory condition and was not taking any other medication apart from natalizumab. She later reported having chickenpox in childhood. She was diagnosed with relapsing-remitting MS in 2013. Treatment with interferon beta-1a was initiated but later-on changed to dimethyl fumarate because of the patient’s preference of tablets over injections. Clinically no relapses were evident, however, radiological monitoring with brain MRI displayed inflammatory disease progression with new gadolinium enhancing lesions during treatment with both drugs, respectively. Therefore, the therapy was switched to natalizumab 2 years after the diagnosis. During treatment with natalizumab, the patient remained stable both clinically and radiologically. Annual JC virus testing (quantitation of virus DNA by real-time PCR) remained negative. In 2021, 6 years after initiation of treatment with natalizumab (56 treatments in total), the patient developed symptoms compatible with right-sided ophthalmic zoster, with blisters over her right forehead and right upper eyelid. She was consulted by her family doctor and, according to the Swedish recommendations, was treated with orally administered valacyclovir 1 g three times per day for 7 days starting immediately. She showed remission at follow-up 10 days later. Two months later, she experienced daily, pounding and pressing bilateral headache which, after 4 weeks, changed to a right-sided occipital and retroorbital pain and after another month ended spontaneously. At this stage, she presented to our neurological outpatient clinic. She had no fever but was sensitive to light and sounds. She also reported isolated recurrent twitches in her right cheek while experiencing the right sided headache; there was no postictal state. The described episodes of twitches were not observed by healthcare professionals as they had terminated spontaneously previous to contact with our unit, neither were they later reported by the patient. No electroencephalogram registration (EEG) was done, and no antiseizure medication was considered necessary. The physical examination was normal except hyper-reflexia in her left arm. Due to the unexplained headaches, brain MRI was performed. Investigations Brain MRI including angiographic and gadolinium enhanced sequences, performed 4 months after the ophthalmic zoster infection, demonstrated the presence of subacute ischaemic changes in the right basal ganglia and the right cerebral peduncle. Narrowing of the supraclinoid segment of the right internal carotid artery (ICA) and the A1 segment of the anterior cerebral artery (ACA) and gadolinium enhancement in the vessel wall of the right ICA and ACA were noted (figure 1). VZV vasculopathy was suspected, and the patient was hospitalised. (A) MR angiography showing stenosis in the right internal carotid artery (ICA), M1 segment of the right middle cerebral artery and A1 segment of the right anterior cerebral artery; (B) black-blood sequence: inflammation right ACI (B1) that disappears after 11 months, while the distal right carotid artery walls remain thicker than contralaterally (B2); (C) diffusion-weighted imaging (DWI) showing subacute ischaemic lesion; (D) fluid-attenuated inversion recovery (FLAIR) sequences showing ischaemic lesion. No parenchymal lesions or vascular changes were detected in the left hemisphere, to explain the short episodes of right facial twitches reported by the patient. However, transient or MRI-negative lesions could not be excluded. A lumbar puncture was performed including analyses of cell count, protein, lactate and glucose as well as a broad microbiological assay since the patient was under immunomodulating treatment. White (<0,003×109/L) and red (<0,0003×1012/L) cell count, glucose (3.6 mmol/L), lactate (1.8 mmol/L) and albumin (155 mg/L) were normal. CSF was positive for VZV-DNA. In serum, VZV IgG was positive, and IgM was at the threshold limit value. All other virological and microbiological CSF and serum PCR investigations were negative (Herpes simplex virus-1 and -2, HHV-6, CMV, EBV, human parechovirus, enterovirus, Borrelia burgdorferi, Cryptococcus neoformans/gatti, Escherichia coli K1, H. influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae). No test for JC virus was performed since there were no clinical signs of encephalopathy and the recent test was negative, 3 months prior to the examination at the outpatient clinic. Additional neuroradiological examinations with CT angiography and MRI including black blood sequences supported the diagnosis (see figure 1). Genetical investigations did not show any pathogenic variation in the POLR3F gene, associated with increased risk for CNS vasculopathy caused by reactivation of VZV. Treatment On admission, the patient was started on methylprednisolone intravenously 1 g once a day, acyclovir intravenously 750 mg three times per day and acetylsalicylic acid 75 mg once a day. After 3 days of methylprednisolone intravenously, she was switched to 50 mg once a day of orally administered prednisolone for 2 days with subsequent tapering of 10 mg per day. The effect of treatment was monitored by continuous clinical examination and a follow-up lumbar puncture 17 days after admission. Treatment with natalizumab was paused. The patient was asymptomatic during in-hospital stay and discharged home after 7 days. Acyclovir was administered intravenously until the follow-up lumbar puncture, when VZV-PCR DNA was negative. Virological and microbiological analyses as above were still negative. In serum, HbsAg, anti-HCV, HIV antibodies and antigen, Treponema pallidum and VZV IgM were negative. VZV IgG was positive, as before. The ratio of CD4+/CD8+ (2.65) as well as CD4 percentage (47%) and count (0.69 x 109 /L) were normal in whole blood. Two weeks after the follow-up lumbar puncture, immunomodulating treatment was reinitiated. Natalizumab treatment was terminated, and she was started on rituximab instead. Outcome and follow-up A follow-up MRI scan of the brain was performed 6 weeks after the MRI preceding hospitalisation and demonstrated persisting vasculitic vessel wall changes in the right ICA and the right ACA. Gadolinium enhancement was still present (see figure 1). The next follow-up MRI scan of the brain was performed 9 months later, demonstrating regression of the gadolinium enhancement in the vessel walls, but persisting vessel wall thickening in the affected vessel segments. No new lesions were found. The patient remained clinically stable to date, 2 years and 2 months later. Discussion We report a rare case of VZV-related cerebral vasculopathy in an adult on long-standing natalizumab treatment. In our patient, the clinical and radiological details of VZV vasculopathy is in line with previous reports, but there are only few reports of VZV vasculopathy in patients with MS and long-standing natalizumab treatment.5 Several questions regarding triggering causes, ischaemic lesions development, the long-term consequences of VZV vasculopathy and the best therapeutical strategy need to be discussed. Our patient presented with headache, which is a common symptom in cerebral vasculopathy, but did not present any typical stroke symptoms.5 Her history of ophthalmic zoster preceding the occurrence of VZV vasculopathy supports previous reports indicating an increased risk in this herpes zoster subtype.1 11 12 In our case, time from rash to presumed symptom onset of VZV vasculopathy was 2 months compared with the reported average time of 4.1 months.13 However, in some cases of VZV vasculopathy, no antecedent rash was reported.10 14 VZV is a neurotropic human alpha-herpesvirus that after the primary infection, which causes chickenpox, becomes latent in ganglionic neurons.15 16 It is considered that the reactivation of the virus can happen spontaneously or by triggering factors such as immunosuppression from disease or drugs and increase in age due to declined cell-mediated immunity.16 Some individuals may also have a hereditary higher risk for reactivation of VZV and development of VZV vasculopathy, but the role of hereditary factors are not established today. Concomitant immunosuppression could further add to this risk.17 In our case, no pathogenic variations in the known associated genes could be found. After reactivation, the virus travels transaxonally to the cerebral arteries where the nerves terminate in the adventitia, with subsequent viral transmural migration to the media. Immune cells are recruited, which then release factors associated with pathological vascular remodelling.18 19 The infection of quiescent primary human perineural cells of VZV has also been directly linked to the production of amylin, amyloid and an amyloidogenic extracellular environment. Thus, except the inflammatory process in the vessel wall and the infection of vascular endothelial cells, the presence of amyloid in VZV-infected cells and CSF could be part of the explanation of the persistent inflammation in VZV-infected arteries, because of chronically activated immune cells due to insoluble amyloid aggregates.18 The long-term consequences of these changes are not yet understood. The role of natalizumab cannot be established for certain, but its immunomodulatory properties make it likely that natalizumab contributed to the development of VZV vasculopathy in our patient. Whereas VZV vasculopathy involves both large and small arteries, the lesions seem to preferentially develop in small vessel territories. Brain imaging abnormalities are very common and typically seen as enhancing lesions at grey-white matter junctions, indicating cerebral ischaemia, infarction or haemorrhage.15 18 Some authors explain this by a denser trigeminal innervation of the middle and ACA, while this is minimal in penetrating vessels supplying the basal ganglia. Branches originating from the trigeminal nerve innervate intracerebral arteries and are considered to be involved in adjusting brain vessel tone and permeability.20 In our patient, vasculitic changes were seen in the right MCA and ACA, and ischaemic changes were evident in the right-sided basal ganglia and cerebral peduncle, which is in line with previous reports. MRI, MR angiography including time-of-flight, black blood sequences and CT angiography images were suggestive for larger intracranial vessel wall inflammation (proximal ACI right, M1 and A1 right). As the literature shows, invasive methods, such as digital subtraction angiography, may increase the diagnostic yield in case other radiological methods are negative. MRA black-blood sequences, however, have been proven to be a reliable method to detect inflammatory changes in the cerebral vessels.21 22 Based on the radiological findings and in the context of the clinical symptom dynamics, lumbar puncture results and the absence of other toxic, renal, cardiac or other comorbidities, we strongly sustain the diagnosis of cerebral zoster vasculopathy. Thus, we exclude conditions such as reversible vasoconstrictive syndrome, atherosclerosis, moyamoya or dissections, that might also manifest with similar, though not entirely identical, appearance on the black-blood sequences. Analysis of the CSF among patients prescribed natalizumab is important even when all reported values fall into normal ranges. Further immunological follow-up is often required and discussion with a specialist in infectious diseases as well as the laboratory can be helpful. JC virus testing is advisable as well. To exclude the diagnosis of VZV vasculopathy, a negative result both for VZV-DNA and anti-VZV antibodies in the CSF is required. However, the detection of anti-VZV IgG antibody in CSF has been shown to be a more sensitive indicator of VZV vasculopathy than detection of VZV DNA.13 15 When the diagnosis of VZV intracerebral vasculopathy is confirmed, intravenously administered acyclovir is recommended for a minimum of 14 days. Empiric treatment awaiting CSF analysis is encouraged. A short course of oral prednisolone to minimise the inflammatory response in the infected arteries is also suggested, with a prolonged course for non-responders. For some patients a prolonged treatment with intravenously acyclovir is recommended, this includes patients who do not respond to initial treatment, develop new MRI lesions or have a persistent pleocytosis in CSF after 2 weeks of treatment.5 This treatment strategy is in line with the management in the majority of the case reports, although most started with intravenously administered methylprednisolone. In one of the case reports continuous prophylactic acyclovir was administered with a restart of natalizumab.10 In the other case reports, when noted, natalizumab was discontinued. There are no controlled trials that have assessed the optimal treatment strategy for patients with intracerebral VZV vasculopathy. Due to the scarcity of cases of herpes virus infections in MS patients, larger studies defining susceptibility to neurotropic viruses during different treatments are also missing.7 23 Therefore, there are no current guidelines considering treatment of intracerebral VZV vasculopathy, nor the management of immunomodulating treatment after an episode of VZV vasculopathy. To date, only 10 cases of VZV associated CNS infection during natalizumab treatment, including the present case, have been reported in English literature (see table 1).9 10 14 23–26 The patients presented with a diversity of symptoms, and most of them did not reach complete remission at the last clinical follow-up; one case was fatal. In these cases, when mentioned, immunosuppressing conditions as HIV were ruled out and natalizumab was the only immunomodulating treatment. In all cases, VZV reactivation was either stated or suspected. As mentioned above, there is no evidence regarding the continuous management of immunomodulating MS treatment. In our patient, natalizumab treatment was terminated and replaced by rituximab, the most widely used disease-modifying therapy for MS in Sweden.27 Table 1Case reports of patients under treatment with natalizumab with VZV vasculopathyReferenceGender (F/M)Previous treatmentStart of natalizumab (year)VZV vasculitis onset (year/age)NTZ treatment at VZV vasculitis onset (months)First symptoms ofVZVClinical outcome at last follow-upBourre et al, 201324FN/AN/AN/A14Thunderclap headache, photophobia, no meningeal signsRecoveredFine et al, 20139FAzathioprine, mitoxantroneN/AN/A / 37 years old7MeningoradiculitisRecoveredFine et al, 20139FNoneN/AN/A / 62 years old23MeningitisRecoveredKobeleva et al, 201425MIFNB-1a20072012 /49 years oldN/AProgressive bilateral visual loss and slight confusion lasting for 2 weeksVisual impairmentMulero et al, 201810FGlatiramer acetate20102016 /48 years old72Headache, unsteady gait, intermittent diplopia, hypoacusiaPartially recoveredvan Kempen et al, 202123FN/A20062019 /59 years oldN/ANeurological complaints followed by visual disturbances of the right eyeDeceasedvan Kempen et al, 202123FN/A20072017 /37 years oldN/ANeurological complaints followed by a red left eye with visual disturbancesVisual impairmentWray, 200826MNoneN/AN/A /51 years old20Headache, muscle pain, chills, small erythematous area right biceps, meningitisRecoveringYeung et al, 201314FNoneN/AN/A /32 years old4MeningomyelitisPartially recoveredOur patient, 2022FIFNB-1a, dimethyl fumarate20152021 /28 years old56Ophthalmic zoster, 2 months later headache, photophobia, audiophobiaRecoveredF, female; M, male; N/A, Not available; VZV, Varicella zoster virus. Case reports of patients under treatment with natalizumab with VZV vasculopathy F, female; M, male; N/A, Not available; VZV, Varicella zoster virus. In conclusion, the presentation of VZV vasculopathy is multifaceted and can, as in our case, manifest with non-specific symptoms and lead to ischaemic stroke. The described case demonstrates an example of a beneficial clinical course in a potentially lethal disease. There is currently insufficient knowledge to explain why certain individuals develop VZV vasculopathy and reliable tools for risk stratification are lacking. Studies are needed to establish treatment recommendations of postinfection MS treatment. With the presented case we also want to raise awareness of less common stroke aetiologies. Learning points The presentation of varicella zoster virus (VZV) vasculopathy is multifaceted, potentially non-specific, and may manifest with ischaemic stroke. The presentation of varicella zoster virus (VZV) vasculopathy is multifaceted, potentially non-specific, and may manifest with ischaemic stroke. Brain imaging abnormalities are common but not obligate in VZV vasculopathy. A negative result both for VZV-DNA and anti-VZV antibodies in the cerebrospinal fluid is required to exclude the diagnosis. Brain imaging abnormalities are common but not obligate in VZV vasculopathy. A negative result both for VZV-DNA and anti-VZV antibodies in the cerebrospinal fluid is required to exclude the diagnosis. Stroke in young patients, especially when treated with immunomodulating drugs, may have unusual aetiologies such as infections and immunologic mechanisms. Stroke in young patients, especially when treated with immunomodulating drugs, may have unusual aetiologies such as infections and immunologic mechanisms. Treatment guidelines for VZV vasculopathy and especially the management of disease-modifying multiple sclerosis treatment postinfection are currently not well established. Treatment guidelines for VZV vasculopathy and especially the management of disease-modifying multiple sclerosis treatment postinfection are currently not well established. Although a rare condition, there is an emerging number of reports of VZV vasculopathy in the context of immunomodulation with natalizumab. Although a rare condition, there is an emerging number of reports of VZV vasculopathy in the context of immunomodulation with natalizumab.